# Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

> **NCT02767934** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 12 (actual)

## Conditions studied

- B Acute Lymphoblastic Leukemia
- Minimal Residual Disease
- Recurrent Acute Lymphoblastic Leukemia
- T Acute Lymphoblastic Leukemia

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02767934
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-13
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-12-17
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Terminated due to lack of efficacy
- **Last updated:** 2020-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02767934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02767934, "Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02767934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*